Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05400330 · ClinicalTrials.gov registry record · Phase 1
Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's Disease
A Phase 1 study of Alzheimer Disease, sponsored by Lexeo Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 2
- Study locations
NCT05400330 is a Phase 1 study of Alzheimer Disease that is active but no longer recruiting, run by Lexeo Therapeutics. The registered enrollment target is 10 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05400330, a Phase 1 study of Alzheimer Disease, is active but no longer recruiting, sponsored by Lexeo Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 2
- Study locations
Study Summary
The primary purpose of this long-term follow-up study is to assess the long-term safety profile of APOE4 homozygote participants who were administered gene therapy (LX1001) for the treatment of Alzheimer's disease in Study LX100101. A secondary objective is to assess the biomarker as shown by the conversion of CSF APOE isoforms from APOE4 to APOE2-APOE4. Additional secondary outcomes include amyloid PET scan, CSF markers (including Aβ42, Aβ42/Aβ40 ratio T--tau, and P-tau), and quantitative MRI (and other biomarkers that may be informative for this therapeutic approach). Other secondary objectives include instruments to assess cognitive and clinical AD and to evaluate if treatment with AAVrh.10hAPOE2 improves brain tau pathology with tau PET scan (LX1001-01 Cohorts 3 and 4 only).
Conditions Studied
Interventions
- BIOLOGICAL LX1001
Study Locations (2)
Florida
- PPD- Orlando Research Unit - Orlando
North Carolina
- Duke University - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2023-05-08 |
| Est. Completion | 2028-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05400330
The ClinicalTrials.gov registry entry for NCT05400330 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (100% lower). The listed sponsor is Lexeo Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which LX1001 is the first listed.
NCT05400330 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, North Carolina.
Frequently Asked Questions
What is clinical trial NCT05400330 about?
NCT05400330 is a clinical study titled "Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's Disease". The primary purpose of this long-term follow-up study is to assess the long-term safety profile of APOE4 homozygote participants who were administered gene therapy (LX1001) for the treatment of Alzheimer's disease in Study LX100101. A secondary objective is to assess the biomarker as shown by the co...
What is the current status of trial NCT05400330?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2023-05-08. Estimated completion is 2028-11.
What conditions does trial NCT05400330 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT05400330?
The interventions under investigation include: LX1001 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05400330?
This trial is sponsored by Lexeo Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05400330 being conducted?
This trial has 2 study locations across Florida, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042
RECRUITING · Phase 1
-
Nicotinic Acid for the Treatment of Alzheimer's Disease
RECRUITING · Phase 1
-
A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01
RECRUITING · Phase 1
-
Deep Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus for Alzheimer Disease (AD)
RECRUITING · Phase 1
-
Assess Fibrin in Brains With AD/ADRD
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.